Our Terms & Conditions | Our Privacy Policy
Drugmaker Lupin Ltd has acquired Huminsulin in India from Eli Lilly and Company, for an undisclosed amount. The move will strengthen Lupin’s diabetes footprint in the country.
Lupin has been marketing the Huminsulin range of products including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, through existing distribution and promotion agreements with Lilly, India, it said.
The Huminsulin range is indicated for type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children. Insulin treatment is the cornerstone of type 1 diabetes management and often becomes necessary over time in type 2 diabetes as the disease progresses, the company said.
“This acquisition is strategic to our ongoing efforts to expand our diabetes portfolio and provide high-quality, affordable health care to our patients,” said Nilesh Gupta, Lupin Managing Director.
Rajeev Sibal, Lupin President (India Region Formulations) said, the acquisition enabled the company to offer a broad range of human insulin options to patients.
SHARE
Published on December 30, 2024
Images are for reference only.Images and contents gathered automatic from google or 3rd party sources.All rights on the images and contents are with their legal original owners.
Aggregated From –
Comments are closed.